OBJECTIVE: To determine the significance of the extent of mesorectal tumor invasion as a prognostic factor for T3 rectal cancer patients. SUMMARY BACKGROUND DATA: There is controversy as to which primary lesion characteristics, other than regional lymph node involvement, in T3 rectal cancer are reliable prognostic factors. PATIENTS AND METHODS: The extent of mesorectal tumor invasion was evaluated using 2 data sets comprising 196 and 247 patients undergoing curative surgery at separate institutes. When the outer aspect of the muscular layer was not identifiable, an estimate was obtained by drawing a straight line between the 2 break points of the muscular layer. RESULTS: We selected 6 mm as the optimal value for subclassification of T3 rectal patients into 2 groups, based on the extent of mesorectal invasion, using the first data set. The overall 5-year survival rate was significantly higher in patients with <6 mm than in those with > or =6 mm of mesorectal invasion (72% versus 50%; P< 0.01). Similarly, in the second data set, the overall 5-year survival rates of patients with mesorectal invasion <6 mm and > or =6 mm were 59% and 37%, respectively (P < 0.01). In both data sets, multivariate analyses verified the extent of mesorectal invasion to be an independent prognostic factor, together with nodal involvement. Regarding positive nodal involvement and mesorectal invasion > or =6 mm as risk factors, the overall 5-year survival rates with none, one, and both of these factors were 84%, 61%, and 38%, respectively, in the first data set (P < 0.01). Prognostic results were similar for the second data set. CONCLUSION: Extent of mesorectal invasion, based on a 6-mm cutoff value, is useful for subclassification of T3 rectal cancer patients.
OBJECTIVE: To determine the significance of the extent of mesorectal tumor invasion as a prognostic factor for T3 rectal cancerpatients. SUMMARY BACKGROUND DATA: There is controversy as to which primary lesion characteristics, other than regional lymph node involvement, in T3 rectal cancer are reliable prognostic factors. PATIENTS AND METHODS: The extent of mesorectal tumor invasion was evaluated using 2 data sets comprising 196 and 247 patients undergoing curative surgery at separate institutes. When the outer aspect of the muscular layer was not identifiable, an estimate was obtained by drawing a straight line between the 2 break points of the muscular layer. RESULTS: We selected 6 mm as the optimal value for subclassification of T3 rectal patients into 2 groups, based on the extent of mesorectal invasion, using the first data set. The overall 5-year survival rate was significantly higher in patients with <6 mm than in those with > or =6 mm of mesorectal invasion (72% versus 50%; P< 0.01). Similarly, in the second data set, the overall 5-year survival rates of patients with mesorectal invasion <6 mm and > or =6 mm were 59% and 37%, respectively (P < 0.01). In both data sets, multivariate analyses verified the extent of mesorectal invasion to be an independent prognostic factor, together with nodal involvement. Regarding positive nodal involvement and mesorectal invasion > or =6 mm as risk factors, the overall 5-year survival rates with none, one, and both of these factors were 84%, 61%, and 38%, respectively, in the first data set (P < 0.01). Prognostic results were similar for the second data set. CONCLUSION: Extent of mesorectal invasion, based on a 6-mm cutoff value, is useful for subclassification of T3 rectal cancerpatients.
Authors: Pascal Gervaz; Jean-Philippe Cerottini; Hanifa Bouzourene; Dieter Hahnloser; Christy L Doan; Jean Benhattar; Pascal Chaubert; Michelle Secic; Michel Gillet; John M Carethers Journal: Surgery Date: 2002-02 Impact factor: 3.982
Authors: Iris D Nagtegaal; Corrie A M Marijnen; Elma Klein Kranenbarg; Cornelis J H van de Velde; J Han J M van Krieken Journal: Am J Surg Pathol Date: 2002-03 Impact factor: 6.394
Authors: Simone Sibio; A Di Giorgio; S D'Ugo; G Palmieri; L Cinelli; V Formica; B Sensi; G Bagaglini; S Di Carlo; V Bellato; G S Sica Journal: Langenbecks Arch Surg Date: 2019-11-23 Impact factor: 3.445
Authors: Thilo Sprenger; Hilka Rothe; Klaus Jung; Hans Christiansen; Lena C Conradi; B Michael Ghadimi; Heinz Becker; Torsten Liersch Journal: World J Surg Oncol Date: 2010-04-13 Impact factor: 2.754
Authors: Søren R Rafaelsen; Chris Vagn-Hansen; Torben Sørensen; John Pløen; Anders Jakobsen Journal: World J Gastroenterol Date: 2012-09-28 Impact factor: 5.742
Authors: Bartlomiej Szynglarewicz; Rafal Matkowski; Agnieszka Halon; Aleksandra Lacko; Marcin Stepien; Jozef Forgacz; Marek Pudelko; Jan Kornafel Journal: Pathol Oncol Res Date: 2009-09-15 Impact factor: 3.201